Saturday 31 July 2021

Pharmacotherapeutic Options for Management of Attention Deficit Hyperactivity Disorder| Chapter 9 | Highlights on Medicine and Medical Science Vol. 9

 The most frequent behavioural disorder in children is attention deficit hyperactivity disorder (ADHD). ADHD can make a person unable for the rest of their lives. The Diagnostic and Statistical Manual of Mental Disorders is used to diagnose ADHD (DSM-5). ADHD is a costly health concern that has been treated with a variety of medicines, including psychostimulants, tricyclic antidepressants (TCAs), bupropion, pemoline, clonidine, and atomoxetine. The most typically recommended medicines for paediatric ADHD are atomoxetine and psychostimulants, both of which have equal efficacy. Atomoxetine has been linked to a number of serious side effects. There have been some reports. Modafinil, a mild psychostimulant, is not approved by the US Food and Drug Administration to treat ADHD, but it is prescribed off-label for this illness. Concurrent psychiatric diseases, such as sleeplessness, tics, PTSD, and violence, necessitate extra consideration while managing a person with ADHD.


Author(s) Details

Jarnail Singh Braich
Department of Pharmacology, Pt. BD Sharma UHS, Rohtak, Haryana, India.

View Book :- https://stm.bookpi.org/HMMS-V9/article/view/2243

No comments:

Post a Comment